← All News
Bloomberg Markets · 1 min read

Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO

Aspen Neuroscience Inc., a clinical-stage developer of cell therapies, fell 2% after raising about $140.6 million in a US initial public offering.

This is a summary aggregated from Bloomberg Markets. Read the complete article on the original site:

Read full article at Bloomberg Markets

More Startup & VC News

Official Starting Lineup: 2026 NASCAR Truck Series Black’s Tire 200 at Martinsville

Yahoo Sports · 23 min ago

Jeremy Ratliff: Commentary: I waited 44 years to see the Brewers win the World Series

Yahoo Sports · 27 min ago

The Google Pixel 11 series just hit a record-low price ahead of Black Friday — and I'd be surprised if it gets cheaper

TechRadar · 1 hr ago

Apple TV has three shows with finales next week, here’s what’s ending

9to5Mac · 1 hr ago

You can expect the stock market to rally no matter who wins on Election Day

MarketWatch · 1 hr ago

Anthropic may not secure investment-grade rating after IPO, Blackstone says

Hacker News · 1 hr ago